Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives $57.33 Consensus Price Target from Brokerages

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) have received an average rating of "Moderate Buy" from the eight brokerages that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $57.33.

A number of research firms have weighed in on AGIO. Bank of America reduced their price target on Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating for the company in a research report on Tuesday, July 22nd. Scotiabank dropped their price objective on Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating on the stock in a research note on Friday, May 2nd. Finally, Wall Street Zen cut Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday, May 19th.

Insiders Place Their Bets

In related news, Director David Scadden sold 1,400 shares of the stock in a transaction on Thursday, July 10th. The stock was sold at an average price of $40.00, for a total value of $56,000.00. Following the sale, the director owned 17,603 shares in the company, valued at approximately $704,120. This represents a 7.37% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Brian Goff sold 18,700 shares of the stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total value of $627,198.00. Following the completion of the sale, the chief executive officer owned 105,401 shares in the company, valued at approximately $3,535,149.54. This trade represents a 15.07% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 46,363 shares of company stock worth $1,619,654 in the last quarter. Company insiders own 4.30% of the company's stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the business. CWM LLC raised its stake in Agios Pharmaceuticals by 218.6% in the 2nd quarter. CWM LLC now owns 5,286 shares of the biopharmaceutical company's stock valued at $176,000 after acquiring an additional 3,627 shares during the period. KLP Kapitalforvaltning AS lifted its holdings in shares of Agios Pharmaceuticals by 18.0% during the second quarter. KLP Kapitalforvaltning AS now owns 11,800 shares of the biopharmaceutical company's stock worth $392,000 after buying an additional 1,800 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Agios Pharmaceuticals by 16.7% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,237 shares of the biopharmaceutical company's stock valued at $74,000 after acquiring an additional 320 shares during the period. Harbor Capital Advisors Inc. grew its stake in shares of Agios Pharmaceuticals by 3.6% in the second quarter. Harbor Capital Advisors Inc. now owns 37,024 shares of the biopharmaceutical company's stock valued at $1,231,000 after acquiring an additional 1,295 shares in the last quarter. Finally, Strs Ohio acquired a new position in shares of Agios Pharmaceuticals in the first quarter valued at about $240,000.

Agios Pharmaceuticals Stock Up 0.9%

Shares of AGIO traded up $0.35 on Thursday, hitting $40.00. The company's stock had a trading volume of 529,138 shares, compared to its average volume of 646,375. The firm's fifty day moving average price is $34.98 and its 200-day moving average price is $32.47. Agios Pharmaceuticals has a fifty-two week low of $23.42 and a fifty-two week high of $62.58. The firm has a market capitalization of $2.32 billion, a price-to-earnings ratio of 3.56 and a beta of 0.73.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share for the quarter, topping analysts' consensus estimates of ($1.80) by $0.25. Agios Pharmaceuticals had a negative return on equity of 2.75% and a net margin of 1,798.26%. The firm had revenue of $8.73 million during the quarter, compared to the consensus estimate of $9.86 million. As a group, equities analysts predict that Agios Pharmaceuticals will post -6.85 earnings per share for the current fiscal year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.